Cargando…

1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination?

BACKGROUND: Congenitally transmitted cytomegalovirus (CMV) is the leading infectious cause of deafness and intellectual impairment among infants. Due to lack of effective preventive and curative treatments, routine CMV screening of pregnant women is generally not recommended by clinical guidelines o...

Descripción completa

Detalles Bibliográficos
Autores principales: Njue, Annete, Marguilis, Andrea, Lyall, Matthew, Nuabor, Weyinmi, Marks, Morgan, Russell, Kevin, Sinha, Anushua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808722/
http://dx.doi.org/10.1093/ofid/ofz360.1643
_version_ 1783461804389695488
author Njue, Annete
Marguilis, Andrea
Lyall, Matthew
Nuabor, Weyinmi
Marks, Morgan
Russell, Kevin
Sinha, Anushua
author_facet Njue, Annete
Marguilis, Andrea
Lyall, Matthew
Nuabor, Weyinmi
Marks, Morgan
Russell, Kevin
Sinha, Anushua
author_sort Njue, Annete
collection PubMed
description BACKGROUND: Congenitally transmitted cytomegalovirus (CMV) is the leading infectious cause of deafness and intellectual impairment among infants. Due to lack of effective preventive and curative treatments, routine CMV screening of pregnant women is generally not recommended by clinical guidelines or public health authorities, but is conducted on an opportunistic basis by specific healthcare systems and providers. This targeted review describes the rate of reported maternal screening for CMV infection and subsequent pregnancy outcomes. METHODS: PubMed and Embase were searched to identify English-language articles reporting the rate of screening for CMV maternal infection (Objective 1), the acceptance rate for diagnostic amniocentesis (Objective 2), and the elective termination rates due to CMV infection (Objective 3) in Europe and Israel. No date limit was applied. RESULTS: Seventeen articles published between 2000 and 2018 were included. Routine CMV screening of pregnant women in the absence of country-level guidelines appears to be common in France and Israel (table). Conversely, in Portugal, where country-level guidelines exist for preconception screening, a high proportion of women are not screened (table). Acceptance rates of diagnostic amniocentesis among women with CMV infection vary considerably across countries, with the highest rates reported in Israel (73%) and the lowest in Italy (16%). Elective termination rates were higher among women who underwent amniocentesis vs. those who did not and those with primary CMV infection vs. those with nonprimary infection. Conversely, one study in Israel showed higher termination rates among patients who did not undergo amniocentesis vs. those who did (35.5% vs. 7.3%). CONCLUSION: The available data indicate that routine screening is carried out in some countries to a variable degree. There is an unmet need for effective prevention and management options to help prevent unnecessary termination of pregnancy. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6808722
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68087222019-10-28 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination? Njue, Annete Marguilis, Andrea Lyall, Matthew Nuabor, Weyinmi Marks, Morgan Russell, Kevin Sinha, Anushua Open Forum Infect Dis Abstracts BACKGROUND: Congenitally transmitted cytomegalovirus (CMV) is the leading infectious cause of deafness and intellectual impairment among infants. Due to lack of effective preventive and curative treatments, routine CMV screening of pregnant women is generally not recommended by clinical guidelines or public health authorities, but is conducted on an opportunistic basis by specific healthcare systems and providers. This targeted review describes the rate of reported maternal screening for CMV infection and subsequent pregnancy outcomes. METHODS: PubMed and Embase were searched to identify English-language articles reporting the rate of screening for CMV maternal infection (Objective 1), the acceptance rate for diagnostic amniocentesis (Objective 2), and the elective termination rates due to CMV infection (Objective 3) in Europe and Israel. No date limit was applied. RESULTS: Seventeen articles published between 2000 and 2018 were included. Routine CMV screening of pregnant women in the absence of country-level guidelines appears to be common in France and Israel (table). Conversely, in Portugal, where country-level guidelines exist for preconception screening, a high proportion of women are not screened (table). Acceptance rates of diagnostic amniocentesis among women with CMV infection vary considerably across countries, with the highest rates reported in Israel (73%) and the lowest in Italy (16%). Elective termination rates were higher among women who underwent amniocentesis vs. those who did not and those with primary CMV infection vs. those with nonprimary infection. Conversely, one study in Israel showed higher termination rates among patients who did not undergo amniocentesis vs. those who did (35.5% vs. 7.3%). CONCLUSION: The available data indicate that routine screening is carried out in some countries to a variable degree. There is an unmet need for effective prevention and management options to help prevent unnecessary termination of pregnancy. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6808722/ http://dx.doi.org/10.1093/ofid/ofz360.1643 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Njue, Annete
Marguilis, Andrea
Lyall, Matthew
Nuabor, Weyinmi
Marks, Morgan
Russell, Kevin
Sinha, Anushua
1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination?
title 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination?
title_full 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination?
title_fullStr 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination?
title_full_unstemmed 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination?
title_short 1780. Congenital Cytomegalovirus: What Are the Rates of Maternal Screening, Diagnostic Amniocentesis, and Elective Termination?
title_sort 1780. congenital cytomegalovirus: what are the rates of maternal screening, diagnostic amniocentesis, and elective termination?
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808722/
http://dx.doi.org/10.1093/ofid/ofz360.1643
work_keys_str_mv AT njueannete 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination
AT marguilisandrea 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination
AT lyallmatthew 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination
AT nuaborweyinmi 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination
AT marksmorgan 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination
AT russellkevin 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination
AT sinhaanushua 1780congenitalcytomegaloviruswhataretheratesofmaternalscreeningdiagnosticamniocentesisandelectivetermination